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PPost-Infarction Myocardial Perfusion Imaging
Multinational Study to Establish
he Value of Early Adenosine Technetium-99m
estamibi Myocardial Perfusion Imaging
n Identifying a Low-Risk Group for Early
ospital Discharge After Acute Myocardial Infarction
ohn J. Mahmarian, MD, FACC,* Leslee J. Shaw, PHD,† Neil G. Filipchuk, MD,‡ Habib A. Dakik, MD,§
herif S. Iskander, MD, Terrence D. Ruddy, MD,¶ Milena J. Henzlova, MD,# Felix Keng, MD,**
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OBJECTIVES The purpose of this study was to determine whether gated adenosine Tc-99m sestamibi single-photon
emission computed tomography (ADSPECT) could accurately define risk and thereby guide
therapeutic decision making in stable survivors of acute myocardial infarction (AMI).
BACKGROUND Controversy continues as to the role of noninvasive stress imaging in stratifying risk early after AMI.
METHODS The INSPIRE (Adenosine Sestamibi Post-Infarction Evaluation) trial is a prospective
multicenter trial which enrolled 728 clinically stable survivors of AMI who had gated
ADSPECT within 10 days of hospital admission and subsequent 1-year follow-up. Event
rates were assessed within prospectively defined INSPIRE risk groups based on the adenosine-
induced left ventricular perfusion defect size, extent of ischemia, and ejection fraction.
RESULTS Total cardiac events/death and reinfarction significantly increased within each INSPIRE risk
group from low (5.4%, 1.8%), to intermediate (14%, 9.2%), to high (18.6%, 11.6%) (p  0.01).
Event rates at 1 year were lowest in patients with the smallest perfusion defects but progressively
increased when defect size exceeded 20% (p  0.0001). The perfusion results significantly
improved risk stratification beyond that provided by clinical and ejection fraction variables. The
low-risk INSPIRE group, comprising one-third of all enrolled patients, had a shorter hospital stay
with lower associated costs compared with the higher-risk groups (p  0.001).
CONCLUSIONS Gated ADSPECT performed early after AMI can accurately identify a sizeable low-risk
group who have a 2% death and reinfarction rate at 1 year. Identifying these low-risk
patients for early hospital discharge may improve utilization of health care resources at
considerable cost savings. (J Am Coll Cardiol 2006;48:2448–57) © 2006 by the American
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.07.069College of Cardiology Foundation
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There is no consensus as to the optimal strategy
for evaluating risk in stable survivors of acute
myocardial infarction (AMI). Ideally, this would
be a noninvasive method which could be per-
formed safely early after AMI so as to accurately
identify low-risk patients and thereby facilitate
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ccepted July 6, 2006.arly hospital discharge. Recent studies in acute coronary
yndromes (ACS) propose that a routine invasive approach
mproves outcome over a conservative strategy of exercise
readmill testing (ETT) followed by selective coronary angiog-
aphy in patients who demonstrate significant myocardial
schemia (1,2). However, preliminary data in patients after
MI suggest that myocardial perfusion imaging, when com-
ined with a pharmacologic vasodilator such as adenosine, is an
See page 2468
ttractive noninvasive method for safely and reliably
tratifying risk early after admission (3–5). The
NSPIRE (Adenosine Sestamibi Post-Infarction Evalu-
tion) is a prospective multinational clinical trial designed
o establish the role of quantitative adenosine
echnetium-99m sestamibi single-photon emission com-
uted tomography (ADSPECT) as the initial primary
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December 19, 2006:2448–57 Adenosine SPECT for Assessing Risk After AMIisk assessment tool for guiding therapeutic decision
aking in stable survivors of AMI.
ETHODS
tudy population. The study cohort consisted of 728
tabilized patients 18 years of age who had either Q- or
on–Q-wave AMI and were prospectively enrolled at 16
ites over 36 months (December 1999 through December
002) with a subsequent 1-year follow-up (6). Study entry
riteria are shown in Table 1.
tudy design. The research protocol was approved by each
ite’s review board, and all patients gave written informed
onsent. The INSPIRE study design is published (6). The
DSPECT was performed within 10 days of hospital admis-
ion using a standard nitrate-enhanced rest-adenosine stress
Abbreviations and Acronyms
ADSPECT  adenosine technetium-99m sestamibi
single-photon emission computed
tomography
ACS  acute coronary syndromes
AMI  acute myocardial infarction
ANOVA  analysis of variance
CI  confidence interval
CR  coronary revascularization
ETT  exercise treadmill testing
GLM  general linear modeling
LVEF  left ventricular ejection fraction
PDS  perfusion defect size
RR  relative risk
SDS  summed difference score
SRS  summed rest score
SSS  summed stress score
TIMI  Thrombolysis In Myocardial Infarction
able 1. Inclusion and Exclusion Criteria (6)
nclusion criteria
1. Chest pain 30 min duration with
a. ST-segment elevation or depression (0.1 mV) in
2 consecutive ECG leads and a rise in cardiac enzymes
 twice the upper limit of normal
OR
b. ST-segment elevation (0.1 mV) in 2 consecutive ECG leads
with development of diagnostic Q waves
2. Age 18 yrs
xclusion criteria
1. Cardiogenic shock
2. Recurrent chest pain unresponsive to anti-ischemic medications
requiring emergency revascularization
3. Uncompensated congestive heart failure
4. Sustained ventricular tachycardia or fibrillation after the first 24 h
5. Acute coronary angiography with primary percutaneous
coronary intervention
6. Left bundle branch block on initial 12-lead ECG
7. Contraindication to adenosine
8. Concomitant noncardiac illness that would limit 1-yr follow-up
9. Premenopausal women unless documented not to be pregnant
10. Inability to give informed consentsCG  electrocardiogram/electrocardiographic.rotocol. The nitrate-enhanced rest study was done to maxi-
ize detection of ischemia (7). Imaging was performed signif-
cantly earlier at U.S. than at non-U.S. sites and irrespective of
nitial clinical risk defined by the Thrombolysis In Myocardial
nfarction (TIMI) risk score (Fig. 1).
Image data were sent electronically to the Nuclear Core
aboratory the day of acquisition for quantification of total and
schemic perfusion defect size (PDS) so as to direct patient
anagement (6). The core laboratory also generated standard
emiquantitative summed stress score (SSS), summed rest
core (SRS), and summed difference score (SDS) (8). A strong
orrelation was seen between SSS and total PDS (r  0.92; p
0.001; PDS 3.34 SSS) and between SDS and ischemic
DS (r  0.91; p  0.0001; ischemic PDS  3.54  SDS).
NSPIRE risk groups. Patient risk and subsequent thera-
eutic decision making were prospectively defined by specific
DSPECT variables (4,5) (Fig. 2). Patients with a small
20%) PDS were classified as low risk and most had a left
entricular ejection fraction (LVEF) of 35% (96%) and an
schemic PDS of 10% (97%). This group was discouraged
rom having coronary angiography unless they developed
linical instability (6). Infarct-free survival at 1 year was
nticipated to be 95%, so ADSPECT results were used to
xpedite hospital discharge (4,5).
Patients with large (20%) but primarily nonischemic
10%) defects were defined as intermediate risk and had
atheterization and coronary revascularization (CR) at investi-
ator discretion (5,6). It was anticipated that most would not
ave CR, because CR does not improve survival over medical
herapy in patients without ischemic (9) or viable (10) myo-
ardium.
Patients with large total (20%) and ischemic (10%)
efects and an LVEF of 35% were defined as high risk and
ncouraged to have coronary angiography, whereas those with
n LVEF 35% were randomized to receive either intensive
edical therapy or CR (6). The results from the randomized
rm of the INSPIRE study are reported elsewhere (11).
dditional therapeutic considerations are listed in Table 2.
ardiac events. Prospectively defined events were cardiac
eath, reinfarction, and readmission for ACS or severe con-
estive heart failure (6). Procedure-related AMIs were identi-
ed based on standard clinical criteria rather than by routine
urveillance with cardiac enzymes. Events were adjudicated by
blinded end point committee. The Data and Safety Moni-
oring Board met at prospectively defined intervals to monitor
tudy conduct and event rates within the assigned groups.
tatistical analysis. The general statistical and cost analysis
lans are published (6). Baseline clinical and ADSPECT
ifferences between INSPIRE risk groups were determined
sing nonparametric methods with chi-squared analysis used
o compare all discrete variables except TIMI risk score, where
Spearman correlation was used. Comparisons of continuous
easures across INSPIRE risk groups were performed using
nalysis of variance techniques. Baseline clinical and scinti-
raphic data are presented as frequency (%) or mean 
tandard deviation.
a
T
t
a
e
s
a
e
S
u
l
(
w
f
for pa
F
e
2450 Mahmarian et al. JACC Vol. 48, No. 12, 2006
Adenosine SPECT for Assessing Risk After AMI December 19, 2006:2448–57The primary end point was time to first cardiac event with
secondary end point of time to cardiac death/reinfarction (6).
he trial had 80% power with a 2-sided type I error of 0.05
o detect differences between INSPIRE risk groups. Risk-
djusted multiple variable Cox proportional hazards modeling
stimated the effect of baseline variables on primary and
econdary end points. In each case, the proportional hazards
ssumption was met. The TIMI risk score for ST-segment
Figure 1. Days from hospital admission to adenosine imagingigure 2. The INSPIRE study design. IPDS  ischemic perfusion defect siz
mission computed tomography.levation AMI was selected for comparison with AD-
PECT, because it is a well-accepted clinical instrument
sed to predict outcome in patients who receive thrombo-
ytics (12) and in more heterogeneous AMI populations
13). The TIMI risk score for ACS was not used, because it
as derived primarily from patients without AMI (14).
Survival curves compared differences in overall and infarct-
ree survival among TIMI and INSPIRE risk groups. Other
tients enrolled at United States (USA) versus non-USA sites.e; LVEF  left ventricular ejection fraction; SPECT  single-photon
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December 19, 2006:2448–57 Adenosine SPECT for Assessing Risk After AMIaseline variables assessed by univariate analysis are those in
able 3 (6). Survival curves were also generated based on total
nd ischemic LVPDS, LVEF, and LV volumes. Unadjusted
elative risk ratios were calculated for scintigraphic variables
ollowed by risk-adjusted estimates of cardiac events control-
ing for the TIMI risk score and LVEF. A final multivariable
odel included PDS, LVEF, and TIMI risk score. Chi-
quared statistic compared a TIMI risk model to one of TIMI
isk and LVEF; TIMI risk, LVEF and total PDS; and TIMI
isk and all 3 variables.
From the Cox model, predicted 1-year event rates were
alculated and compared using analysis of variance
ANOVA) or general linear modeling (GLM). Total and
schemic PDS and LVEF were plotted in relation to
redicted event rates. From a Cox model including total and
schemic PDS, event rates from 10% to 75% were calculated
or specific total and ischemic PDS values. A final analysis
ompared predicted event rates from low to high INSPIRE
isk groups based on gender, age, and infarct location.
ost analysis. Six U.S. sites participated in the cost sub-
tudy, and each patient allowed access to their hospital bills.
linded summary charge reports for the index hospitaliza-
ion were obtained from each hospital’s finance office and
ent to the coordinating center. Total charges were adjusted,
sing a top-down approach, by multiplying total hospital
harges by the hospital-specific cost-charge ratio. This
stimated hospital cost was then discounted at a 5% annual
ate and inflation-corrected by the U.S. medical service
ector estimate of the consumer price index. Cost estimates
ere available for 205 INSPIRE patients and compared
cross INSPIRE risk groups using ANOVA or GLM.
onparametric statistics were used owing to the nonlinear-
ty of cost data, but in every case this analysis was similar to
he ANOVA or GLM results.
Total hospital length of stay and time spent in intensive
able 2. Therapeutic Considerations (6)
1. Patients routinely received aspirin (325 mg/day) unless
contraindicated
2. Patients routinely received treatment for hyperlipidemia to reduce
low-density lipoprotein cholesterol to 100 mg/dl
3. Patients with an LVEF 40% and/or anterior AMI were encouraged
to receive an angiotensin-converting enzyme inhibitor and a beta-
blocker
4. Anti-ischemic medical therapy was encouraged in patients who had
residual angina and/or ischemia
5. Patients who developed recurrent angina refractory to medical therapy
or other evidence of clinical instability were encouraged to have
coronary angiography
6. Coronary artery bypass surgery was recommended over PCI in
patients with
a. 50% left main stenosis
b. 3-vessel coronary artery disease
c. Diabetes and multivessel disease
7. Poor revascularization candidates were managed medically with
titration of therapy as tolerated
MI  acute myocardial infarction; LVEF  left ventricular ejection fraction;
CI  percutaneous coronary intervention.are units were available for all patients. These surrogates tor resource intensity and infarct severity were compared
cross INSPIRE risk groups using GLM techniques adjust-
ng for baseline TIMI risk score.
ESULTS
aseline patient characteristics and differences across
NSPIRE risk groups. Mean patient age for the entire
NSPIRE cohort was 63 12 years, 31% were women, and
7% had prior AMI (Table 3). The AMI location was
nterior in 32% of patients, and 48% developed Q waves.
ean LVPDS was 26% (with 10% ischemia), and mean
VEF 46  14%. Ischemic PDS was comparably small in
ow (2.8 3%) and intermediate (3.7 3%) INSPIRE risk
roups, but significantly increased in high-risk (23.7 
2%) and randomized (21.3  9%) populations (Table 3).
atients were evenly distributed into low (36% vs. 32%),
ntermediate (28% vs. 30%), high (10% vs. 9%), and
andomized (26% vs. 29%) INSPIRE risk groups across
.S. and non-U.S. sites, respectively (p  NS).
ardiac events. Over a mean follow-up of 11  3 months,
5 events occurred in 88 patients (12.1%) as follows: cardiac
eath, sudden (n  10) or nonsudden (n  8); nonfatal
einfarction (n 34); and readmission for ACS (n 24) or
ongestive heart failure (n  12). Patient follow-up was
omplete at 1 year in 98%. No adenosine- or other
rocedure-related events occurred.
oronary angiography, CR, and events. Few low-risk
atients had initial or late invasive procedures (Table 4). In
he intermediate-risk group, coronary angiography and CR
ere performed in 31% and 17% of patients by 1 month,
hich minimally increased by 1 year. Most high-risk pa-
ients had coronary angiography and subsequent CR, gener-
lly early after AMI. Coronary revascularization significantly
owered event rates in only the high-risk group (Table 4).
utcome based on TIMI risk score and clinical vari-
bles. Cardiac event rates significantly increased with in-
reasing TIMI risk score from low (8%) to intermediate
12.5%) to high (22%) (p  0.042). A similar trend was
bserved when analysis was limited to cardiac death/
einfarction (p  0.07). Univariate risk predictors for
eath/reinfarction were age (relative risk [RR] 1.03/year,
5% confidence interval [CI] 1.01 to 1.06; p  0.01) and
eak troponin I (RR 1.01/U increase, 95% CI 1.0 to 1.01;
 0.0001), and for all events they were diabetes mellitus
RR 1.77, 95% CI 1.17 to 2.68; p  0.006) and peak
roponin I (RR  1.01; 1.0 to 1.01/U increase; p  0.009).
utcome based on INSPIRE risk group. Overall cardiac
p  0.007) (Fig. 3A) and death/reinfarction (p  0.009)
Fig. 3B) event rates significantly increased across INSPIRE
isk groups from low (5.4% and 1.8%) to intermediate
14.0% and 9.2%) to high (18.6 and 11.6%), respectively.
hese differences were observed despite a high initial rate of
R (50%) in the high-risk group. After adjustment for the
IMI risk score, INSPIRE risk categories still predictedotal (p  0.01) and death/reinfarction (p  0.02) events.
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Adenosine SPECT for Assessing Risk After AMI December 19, 2006:2448–57utcome based on total and ischemic PDS. Total and
schemic LV PDS predicted patient outcome both before
Table 5A) and after (Table 5B) adjustment for TIMI risk
core and LVEF (Table 5C). Each 10% absolute increment in
otal or ischemic PDS increased the unadjusted relative risk for
ny event by 37% and 64%, respectively. The extent of
cintigraphic scar also predicted outcome (Tables 5A and 5B),
able 3. Overall Baseline Clinical and Scintigraphic Characteristi
isk Groups
All Patients
(n  728)
Low
(n  242
ge (yrs) 63  12 63  12
emale gender 31% 42%
ace
African 10% 15%
Hispanic 5% 3%
Asian 6% 5%
Caucasian 75% 75%
Other 4% 2%
eart rate (beats/min) 75  15 74  14
ypertension (BP 140/90 mm Hg) 58% 62%
iabetes 30% 23%
amily history of CAD 27% 27%
yperlipidemia 62% 60%
otal cholesterol 205  56 207  51
DL cholesterol 115  45 118  49
DL cholesterol 42  14 42  12
riglycerides 175  145 177  14
moking history 58% 59%
rior CAD 28% 20%
rior AMI 17% 9%
illip class
I 70% 89%
II 18% 10%
III–IV 12% 1%
eak creatine kinase 960  1,032 652  61
eak creatine kinase-MB 68  96 46  62
eak troponin T 6.2  42 1.1  1
eak troponin I 28.3  56 22.7  37
TEAMI 60% 53%
-wave AMI 48% 39%
MI location
Anterior 32% 22%
Inferior 38% 44%
Lateral 10% 10%
Posterior 2% 2%
Other 18% 23%
hrombolytic therapy 35% 32%
hrombolytic therapy for STEAMI 58% 61%
IMI risk score
Low (0–2) 57% 62%
Intermediate (3–5) 35% 33%
High (6) 8% 5%
otal PDS (%) 26.3  17 7.4  6
car PDS (%) 16.1  15 4.6  5
schemia PDS (%) 10.2  11 2.8  3
VEF (%) 46  14 57  12
alues expressed as mean  standard deviation or percentage.
AMI  acute myocardial infarction; BP  blood pressure; CAD  coronary arte
ost-Infarction Evaluation trial; LDL  low-density lipoprotein; LVEF  left vent
cute myocardial infarction; TIMI  Thrombolysis In Myocardial Infarction.ut not after adjustment for LVEF (Table 5C). The comple- pentary prognostic information obtained from total and isch-
mic PDS are depicted in Figure 4.
utcome based on LVEF and cardiac volumes. Relative risk
or any event or death/reinfarction significantly increased as
VEF decreased (Table 5A) and irrespective of TIMI risk
core (Table 5B). An LVEF 50% predicted a low 1-year
vent rate (5%), which increased to 27% in the 3% of
the Study Population and Differences Across INSPIRE
Intermediate
(n  213)
High
(n  68)
Randomized
(n  205) p Value
63  12 64  12 64  12 0.69
28% 25% 24% 0.0001
0.007
11% 10% 5%
8% 9% 4%
8% 1% 6%
71% 80% 82%
2% 0% 3%
74  25 82  16 77  51 0.19
53% 64% 57% 0.16
36% 41% 28% 0.006
27% 26% 27% 0.9
60% 73% 65% 0.15
203  72 202  47 206  42 0.82
112  46 114  46 113  40 0.82
43  20 40  12 41  11 0.45
155  139 174  142 193  150 0.07
58% 68% 55% 0.29
31% 51% 28% 0.0001
21% 30% 18% 0.0001
0.0001
60% 44% 66%
34% 25% 10%
6% 31% 23%
1,423  1,390 1,110  1,069 781  765 0.0001
87  119 96  122 61  83 0.0001
19.7  81 4.4  7 1.4  3 0.14
39.2  71 29.4  74 22.5  50 0.19
74% 66% 50% 0.0001
63% 57% 42% 0.0001
0.0001
46% 52% 22%
34% 19% 43%
7% 13% 13%
4% 0% 2%
8% 16% 20%
45% 25% 30% 0.002
59% 38% 60% 0.006
0.006
57% 62% 50%
36% 31% 38%
8% 7% 12%
36.1  13 44.2  12 32.6  10 0.0001
32.3  13 20.5  20 11.3  11 0.0001
3.7  3 23.7  12 21.3  9 0.0001
37  13 28  8 48  9 0.0001
ease; HDL  high-density lipoprotein; INSPIRE  Adenosine Sestamibi SPECT
ejection fraction; PDS  perfusion defect size; STEAMI  ST-segment elevationcs of
)
5
2
ry dis
ricularatients with an LVEF 20%.
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December 19, 2006:2448–57 Adenosine SPECT for Assessing Risk After AMILeft ventricular end-diastolic and end-systolic volumes
lso predicted events (Tables 5A and 5B) but not after
djustment for LVEF (Table 5C). This is explained by the
trong inverse relationship between LVEF and end-
iastolic (r  0.76; p  0.001) and end-systolic (r  0.91;
 0.001) volumes.
ncremental prognostic value of ADSPECT variables
eyond TIMI risk score. The INSPIRE risk assessment
ignificantly increased the baseline TIMI risk score global
hi-square statistic from 4.7 to 16.5 (total events) and from
.2 to 15.7 (death/reinfarction) (both p  0.001).
The addition of total and ischemic PDS to the combined
IMI risk score and LVEF significantly improved the
odel for predicting all events, but only total PDS added to
he risk model for predicting death/reinfarction (Fig. 5).
he global chi-square also significantly increased when
DS was added first to the TIMI risk score before LVEF (p
0.001).
ultivariate risk predictors. By stepwise logistic regres-
ion, total PDS emerged as the most important independent
isk predictor (p 0.0001), followed by ischemic PDS (p
.005) and LVEF (p 0.05) (Table 6). The only significant
redictor of death/reinfarction was total PDS.
utcome based on the INSPIRE trial risk among patient
ubgroups. The value of ADSPECT was assessed in sev-
ral clinically relevant and prospectively defined patient
ubgroups (6) (Fig. 6). Irrespective of patient age, gender, or
MI location, the INSPIRE risk criteria stratified patients
n a similar fashion as observed in the overall population.
able 4. Coronary Angiography, Revascularization, and Events
INSPIRE Risk Group
Coronary Angiography
(% Patients)
1 Month 3 Months 1 Year
ow 15 18 21
ntermediate 31 34 35
igh 75 82 82
R  coronary revascularization.Figure 3. Total (A) and cardiac death/reinfarctionvent rates were consistently low in all patient subgroups
hat were identified as low risk by ADSPECT.
ost analysis and length of hospital stay. Low-risk IN-
PIRE patients spent fewer days in the coronary care unit,
ere discharged home earlier, and had a better 1-year
utcome than those in the higher-risk groups (p  0.0001)
Table 7). This translated into significantly lower hospital
osts in the low-risk group compared with the intermediate-
nd high-risk INSPIRE groups, where invasive diagnostic
nd interventional therapeutic procedures were more fre-
uently used.
ISCUSSION
he INSPIRE study is the largest prospective trial yet
ompleted to use gated ADSPECT for the purpose of
tratifying risk and thereby guiding therapeutic decision
aking in clinically stable patients early after AMI. The
NSPIRE cohort alone doubles the current published ob-
ervational experience with pharmacologic SPECT imaging
n the post-AMI arena and allowed for risk stratification
ithin a patient population demographically similar to that
een in other recent trials (13,15,16). The INSPIRE results
stablish that the commonly measured scintigraphic vari-
bles of total and ischemic PDS significantly improve the
recision for assessing risk beyond that provided by the
IMI risk score alone or when combined with LVEF.
ated ADSPECT also identified a large group of patients
ith small and/or minimally ischemic defects, where an
Coronary Revascularization
(% Patients) Event Rates (%)
onth 3 Months 1 Year CR No CR p Value
1 13 16 6.9 7.0 0.97
7 20 21 13.9 14.7 0.84
0 62 64 10.0 32.0 0.0491 M
1
1
5(B) rates based on INSPIRE risk categories.
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Adenosine SPECT for Assessing Risk After AMI December 19, 2006:2448–57nitial conservative approach of medical therapy is a reason-
ble alternative to an invasive evaluation.
tudy design features. The refinements in risk stratifica-
ion we report are attributable to several unique study
esign features incorporated in the INSPIRE trial: 1) the
maging protocol used a nitrate-enhanced rest followed
y an ADSPECT stress study to optimize image quality
nd allow accurate quantification of myocardial ischemia
nd LVEF; 2) online quantitative SPECT analysis
hrough a central core laboratory provided uniform image
nterpretation; 3) domestic and international investiga-
ors were enlisted to ensure enrollment of a large and
iverse patient population; 4) the protocol encouraged
dherence to specific and currently accepted medical and
nterventional therapeutic strategies; 5) patient risk was
rospectively defined by ADSPECT within days of
dmission and then verified by a 1-year outcome analysis;
nd 6) the value of ADSPECT for predicting outcome
as analyzed in relation to the TIMI risk score.
DSPECT for assessing risk and guiding therapeutics. The
ornerstone of risk stratification in stable AMI survivors is
o rapidly identify high-risk patients who might benefit
rom CR and low-risk patients for whom medical therapy
nd early hospital discharge is appropriate. The INSPIRE
able 5. Relative Risks for Cardiac Events Based on Gated ADS
A. Unadjusted Relative Risks for Cardiac E
Variable
All Events
Chi-Square RR (95% CI)
otal PDS* 31.5 1.37 (1.23–1.54)
schemic PDS* 32.2 1.64 (1.38–1.95)
car PDS* 11.6 1.23 (1.09–1.39)
VEF† 22.9 1.42 (1.23–1.64)
VEDV‡ 7.9 1.05 (1.01–1.08)
VESV‡ 12.9 1.06 (1.03–1.10)
B. TIMI Risk Score Adjusted Relative Risks for C
Variable
All Events
Chi-Square RR (95% CI)
otal PDS* 30.5 1.37 (1.23–1.53)
schemic PDS* 30.1 1.63 (1.37–1.94)
car PDS* 11.3 1.23 (1.09–1.39)
VEF† 22.5 1.41 (1.23–1.63)
VEDV‡ 9.2 1.05 (1.02–1.09)
VESV‡ 13.9 1.06 (1.03–1.10)
C. TIMI Risk Score and LVEF Adjusted Relative Risks
Variable
All Events
Chi-Square RR (95% CI)
otal PDS* 8.0 1.26 (1.07–1.48)
schemic PDS* 17.8 1.48 (1.23–1.78)
car PDS* 0.0 1.01 (0.91–1.04)
VEDV‡ 0.8 0.97 (0.92–1.03)
VESV‡ 0.6 0.97 (0.91–1.04)
Based on 10% absolute increases in total, ischemic, or scar PDS; †Based on 10% ab
ADSPECT  adenosine Tc-99m sestamibi single-photon-emission computed tom
SV  end-systolic volume; LV  left ventricular; PDS  perfusion defect size; Rtudy achieved this goal by using perfusion imaging to rtratify a heterogeneous post-AMI population into several
istinct risk categories.
The most clinically relevant primary observation is that
DSPECT can accurately identify a large low-risk popu-
ation irrespective of age, gender, site of infarction, or
linical risk. This low-risk group, which represented one-
hird of all enrolled patients, had small (20%) perfusion
efects, preserved LV function, and minimal (10%) resid-
al ischemia. Previous studies in patients with chronic
oronary artery disease or prior AMI have suggested that
R does not improve outcome beyond medical therapy
hen there is minimal (10%) (9) or no (17) provokable
schemia. In support of this, our low-risk group had the
owest rate of CR, the shortest hospital stay, the lowest
ospital-related costs, and yet the lowest (1.8%) cumulative
eath and reinfarction rate at 1 year. In most centers these
ow-risk patients would typically have undergone coronary
ngiography followed by percutaneous coronary interven-
ion of any residual coronary stenosis. However, the
NSPIRE trial demonstrates that such patients can be
edically managed with a quite acceptable low overall event
ate and, compared with invasive treatment, at a cost savings
pproaching 65% (18).
The prospectively defined intermediate-risk group rep-
T Variables
Based on ADSPECT Variables (n  728)
Death/Reinfarction
alue Chi-Square RR (95% CI) p Value
001 20.5 1.40 (1.21–1.62) 0.0001
001 13.6 1.56 (1.23–1.98) 0.0002
007 10.5 1.29 (1.11–1.51) 0.001
001 11.3 1.38 (1.14–1.67) 0.0008
05 5.0 1.05 (1.01–1.10) 0.026
003 6.9 1.06 (1.02–1.11) 0.009
Events Based on ADSPECT Variables (n  728)
Death/Reinfarction
alue Chi-Square RR (95% CI) p Value
001 19.9 1.40 (1.21–1.62) 0.0001
001 12.6 1.54 (1.21–1.96) 0.0004
008 10.3 1.29 (1.10–1.51) 0.0013
001 11.0 1.38 (1.14–1.66) 0.0009
02 5.8 1.05 (1.01–1.10) 0.016
002 7.5 1.06 (1.02–1.11) 0.006
ardiac Events Based on ADSPECT Variables (n  728)
Death/Reinfarction
alue Chi-Square RR (95% CI) p Value
005 7.7 1.35 (1.09–1.67) 0.005
0001 7.1 1.41 (1.09–1.81) 0.008
92 1.2 1.13 (0.91–1.40) 0.26
37 0.0 1.00 (0.93–1.07) 0.90
43 0.0 0.99 (0.91–1.09) 0.87
decreases in LVEF; ‡Based on 10-ml increases in EDV or ESV.
hy; CI  confidence interval; EDV  end-diastolic volume; EF  ejection fraction;
elative risk; TIMI  Thrombolysis In Myocardial Infarction.PEC
vents
p V
0.0
0.0
0.0
0.0
0.0
0.0
ardiac
p V
0.0
0.0
0.0
0.0
0.0
0.0
for C
p V
0.
0.
0.
0.
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soluteesented an additional 29% of patients who would un-
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December 19, 2006:2448–57 Adenosine SPECT for Assessing Risk After AMIikely benefit from an initial invasive approach and for
hom hospital costs could be reduced up to 25% (18).
lthough this group was anticipated to have a higher
igure 4. Predicted 1-year total and death/reinfarction event rates (with
tandard error bars) based on total (A) and ischemic (B) perfusion defect
ize (PDS) and their combination (C). The isobars in C (range 10% to
5%) depict risk for any event. For a patient with a 30% nonischemic PDS,
he predicted event rate is 11% (solid circle), versus 25% if the defect is all
schemic (open circle). LV  left ventricle.vent rate than the low-risk group based on their larger potal PDS and more severe LV dysfunction (4,5), they
ad only minimal residual ischemic myocardium to re-
ascularize. It is not surprising that CR did not alter
vent rates in this group.
The prospectively defined high-risk INSPIRE group had
he longest hospital stay, the highest rate of CR, and the
ighest hospital-related costs but represented only 9% of
atients. Patients in this group had the highest 1-year
verall event rate (18%), particularly when not revascular-
zed. Other trials also suggest that patients with extensive
schemic viable myocardium and a low LVEF benefit most
rom CR (10). The cost analysis from the INSPIRE trial
ighlights the substantial increase in hospital expenses
ttributable to coronary interventional procedures. Gated
DSPECT can specifically identify high-risk ischemic
atients so as to properly allocate health care resources.
revious studies. Previous smaller or retrospective obser-
ational studies suggest that low- and high-risk groups can
e identified using exercise (19–21) or pharmacologic stres-
or agents (3–5) when combined with perfusion scintigra-
hy. The Veterans Affairs Non–Q-Wave Infarction Strat-
gies in Hospital trial successfully used planar imaging to
isk-stratify patients following non–Q-wave AMI (15,22).
he Invasive Versus Conservative Treatment in Unstable
oronary Syndromes trial recently showed that patients
ith non–Q-wave AMI have a similar outcome whether
nitially evaluated with an invasive or a conservative ap-
roach (23).
In contrast, the FRISC-II (Fragmin and Fast Revascu-
arization During Instability in CAD) (2) and TACTICS
Treat Angina With Aggrastat and Determine Cost of
herapy With Invasive or Conservative Strategy) (1) studies
eported superiority of a routine invasive approach over a
oninvasive strategy of ETT and selective angiography in
atients with ACS. Both are particularly germane to the
NSPIRE trial in that they have strongly influenced current
ractice guidelines; and, within the cardiology community,
ave expanded the existing widespread use of an invasive
pproach to now include patients with AMI. These trials
hose ETT as the noninvasive testing standard—a subop-
imal technique for detecting ischemia (20,21) or predicting
isk compared with perfusion imaging (3,20). Furthermore,
n the TACTICS study40% of all cardiac events occurred
n the conservative strategy before the index stress test. The
linical benefit of an early invasive approach in the TAC-
ICS study was based solely on event rate differences within
his early critical time period; patient outcome in both
roups was comparable beyond 30 days. The TIMI experi-
nce in 20,101 patients emphasizes that reinfarction after
hrombolytic therapy occurs generally within 3 days of
dmission (16). Because events recur early after AMI, a
watchful waiting” approach is not clinically acceptable but
enerally unavoidable when ETT is selected as the stressor
odality. By using adenosine in the INSPIRE trial, 54% ofatients were imaged safely within 2 days of admission,
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Adenosine SPECT for Assessing Risk After AMI December 19, 2006:2448–57acilitating very early identification and treatment of high-
isk patients.
tudy limitations. We did not track the percentage of
ligible patients who were enrolled in the INSPIRE trial.
owever, based on previous trials, up to 70% of AMI
atients are clinically stable and would be good candidates
or initial evaluation with ADSPECT (24,25). The TIMI
isk score for ST-segment elevation AMI may not be
ntirely applicable to our population, because not all had
T-segment elevation even though all patients had AMI.
inally, although routine surveillance with cardiac enzymes
as not performed after invasive procedures to identify
ubclinical AMI, it is unlikely that ADSPECT would have
redicted such procedure-related events.
onclusions. Gated ADSPECT is a safe and accurate
nitial method for identifying: 1) a very large low-risk
roup after AMI who can be targeted for medical therapy
nd early hospital discharge; 2) patients with predominantly
car where initial medical treatment is appropriate; and 3)
hose with extensive ischemia where intensive medical and/or
nterventional therapy is warranted. This is a cost-efficient
aradigm already embraced in clinical practice for evaluating
isk and guiding therapeutic decision making in patients
ith suspected or known CAD (26). The findings from the
NSPIRE trial provide justification for recommending that
Figure 5. The incremental prognostic value of scintigraphic var
able 6. Multivariate Predictors of Risk
Variable
All Events Death/AMI
Chi-Square p Value Chi-Square p Value
otal PDS 31.72 0.0001 19.72 0.0001
schemic PDS 7.90 0.005 1.62 0.20
VEF 3.78 0.05 1.35 0.24
IMI risk score 2.35 0.12 0.39 0.53MI  acute myocardial infarction; LVEF  left ventricular ejection fraction;
DS  perfusion defect size; TIMI  Thrombolysis In Myocardial Infarction.
m
rDSPECT be incorporated within current practice guide-
ines as an appropriate initial strategy for risk-stratifying
table survivors of ST-segment elevation AMI who do not
compared with TIMI risk score. Abbreviations as in Figure 2.
igure 6. Predicted event rates (95% confidence intervals) in low, inter-
ediate, and high INSPIRE risk groups in selected subpopulations. MI 
yocardial infarction. *p  0.0001 for low risk versus intermediate, high
isk; †p  0.039 for low risk versus intermediate, high risk.
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atients with non–ST-segment elevation AMI.
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